Tracking the path forward when lymphoma treatment stops working
NCT ID NCT07310186
Summary
This study aims to understand what happens when a common lymphoma treatment stops working. Researchers will follow 200 patients in China whose diffuse large B-cell lymphoma progressed after receiving polatuzumab vedotin-based therapy. By observing which treatments doctors choose next and how patients respond, the study seeks to gather real-world data to help guide future treatment decisions for similar cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.